OBJECTIVE: The CYP2D6 enzyme plays a major role in converting tamoxifen to its active metabolites. We investigated whether there is an association between the CYP2D6*10 allele and clinical outcome in node-negative Japanese breast cancer patients. METHODS: CYP2D6 genotyping was performed in 154 node-negative breast cancer patients who had received adjuvant tamoxifen treatment alone. The CYP2D6 genotypes were determined using the TaqMan Allelic Discrimination Assay. RESULTS: Eighteen percent (28 of 154) of the patients carried the CYP2D6*10/*10 genotype, 40% the CYP2D6 wild-type (wt)/*10 genotype and 42% the CYP2D6 wt/wt genotype. There were no discernible correlations between clinicopathologic parameters and the CYP2D6*10 genotype. Next, we determined whether there was a correlation between the CYP2D6*10 genotype and survival and found that the clinical outcome for patients carrying the CYP2D6*10/*10 genotype was similar to those with other genotypes. CONCLUSIONS: Our results suggest that the CYP2D6*10 genotype is unlikely to have any clinical significance for prognosis of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen alone.
OBJECTIVE: The CYP2D6 enzyme plays a major role in converting tamoxifen to its active metabolites. We investigated whether there is an association between the CYP2D6*10 allele and clinical outcome in node-negative Japanese breast cancerpatients. METHODS:CYP2D6 genotyping was performed in 154 node-negative breast cancerpatients who had received adjuvant tamoxifen treatment alone. The CYP2D6 genotypes were determined using the TaqMan Allelic Discrimination Assay. RESULTS: Eighteen percent (28 of 154) of the patients carried the CYP2D6*10/*10 genotype, 40% the CYP2D6 wild-type (wt)/*10 genotype and 42% the CYP2D6 wt/wt genotype. There were no discernible correlations between clinicopathologic parameters and the CYP2D6*10 genotype. Next, we determined whether there was a correlation between the CYP2D6*10 genotype and survival and found that the clinical outcome for patients carrying the CYP2D6*10/*10 genotype was similar to those with other genotypes. CONCLUSIONS: Our results suggest that the CYP2D6*10 genotype is unlikely to have any clinical significance for prognosis of node-negative Japanese breast cancerpatients receiving adjuvant tamoxifen alone.
Authors: L K Teh; N I Mohamed; M Z Salleh; M Rohaizak; N S Shahrun; J J Saladina; J K S Shia; H Roslan; S Sood; T S Rajoo; S P Muniandy; G Henry; H A Ngow; K T Hla U; J Din Journal: AAPS J Date: 2011-12-20 Impact factor: 4.009
Authors: Mariella De Ameida Melo; Rodrigo José De Vasconcelos-Valença; Fidelis Manes Neto; Rafael Soares Borges; Danylo Rafhael Costa-Silva; Maria Da Conceição Barros-Oliveira; Umbelina Soares Borges; Airlane Pereira Alencar; Vladimir Costa Silva; Benedito Borges Da Silva Journal: Biomed Rep Date: 2016-10-04